FDA approves BMS’ Opdivo, Yervoy combo for malignant pleural mesothelioma

Bristol Myers Squibb (BMS) has secured approval for Opdivo (nivolumab) and Yervoy (ipilimumab) combination from the US Food and Drug Administration (FDA) for the first-line ... Read More